3 results
Not approvedWill not start
The purpose of this study is to evaluate whether there are differences in duration and intensity at a femoral nerve block with ropivacaine Klaris standard 30ml 0.2% with and without addition of buprenorphine (Temgesic ®) 0.3 mg buprenorphine…
Approved WMORecruiting
To explore the efficacy and safety of an oral IP receptor agonist in an inoperable or persistent/recurrent CTEPH population treated with standard of care.
Approved WMOCompleted
The aim of the present study is to investigate whether selexipag could be helpful to treat patients with another form of PH called sarcoidosis-associated pulmonary hypertension (SAPH).